CAR T cells produced in vivo to treat cardiac injury
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Making CAR T cells in vivo: Cardiac fibrosis is the stiffening and scarring of heart tissue and can be fatal. Rurik et al . designed an immunotherapy strategy to generate transient chimeric antigen receptor (CAR) T cells that can recognize the fibrotic cells in the heart (see the Perspective by Gao and Chen). By injecting CD5-targeted lipid nanoparticles containing the messenger RNA (mRNA) instructions needed to reprogram T lymphocytes, the researchers were able to generate therapeutic CAR T cells entirely inside the body. Analysis of a mouse model of heart disease revealed that the approach was successful in reducing fibrosis and restoring cardiac function. The ability to produce CAR T cells in vivo using modified mRNA may have a number of therapeutic applications. —PNK
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“We used an Ang II/PE infusion model to study cardiac fibrosis which has inherent limitations3,4,7,39”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recent advances in CAR T-cell technology have provided a much needed breakthrough and indicated that selectively removing activated cardiac fibroblasts that express fibroblast activator protein (FAP) is sufficient to ameliorate fibrosis without impacting the structural integrity of the heart in preclinical mouse models 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Recent studies have implicated a potential pathogenic role for FAP+ fibroblasts in mouse models of cardiac remodelling3,4.”
From Targeting immune–fibroblast cell communication in heart failure (2024) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“LNPs and CAR-T cells have been combined for antifibrotic therapy in experimental heart fibrosis by administering LNPs that reprogram host lymphocytes into CAR-T cells in order to target cardiac myofibroblasts that express fibroblast activation peptide alpha (FAP) (129).”
From Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH) (2023) · cites this paper as [129]
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies have utilized chimeric antigen receptor (CAR) T cells to target FAP + fibroblasts in a mouse model of cardiac injury and shown improved cardiac function and diminished fibrosis 9,10 .”
From Targeting the Immune-Fibrosis Axis in Myocardial Infarction and Heart Failure (2022) · cites this paper as [10]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
Self-citationKarikó, K., Buckstein, M., Ni, H., & Weissman, D. (2005) · Immunity · doi:10.1016/j.immuni.2005.06.008 · Cited by 2,728
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Self-citationFibrosis: from mechanisms to medicines
Henderson, N. C., Rieder, F., & Wynn, T. A. (2020) · Nature · doi:10.1038/s41586-020-2938-9 · Cited by 1,868
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
Self-citationFibroblast-specific TGF-β–Smad2/3 signaling underlies cardiac fibrosis
Khalil, H., Kanisicak, O., Prasad, V., Correll, R. N., Fu, X., Schips, T., Vagnozzi, R. J., Liu, R., Huynh, T., Lee, S.-J., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94753 · Cited by 905
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2016) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 867
Cited by
Items 301–400 of 1,001
Torimoto, K., Elliott, K., Nakayama, Y., Yanagisawa, H., & Eguchi, S. (2024) · Cardiovascular Research · doi:10.1093/cvr/cvae044 · Cited by 38
Tailoring Highly Branched Poly(β-amino ester)s for Efficient and Organ-Selective mRNA Delivery
Yong, H., Lin, L., Li, Z., Guo, R., Wang, C., Liu, S., & Zhou, D. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02440 · Cited by 38
Fu, C., Jin, X.-Q., Ji, K., Lan, K. N., Mao, X., Huang, Z., Chen, J., Zhao, F., Li, P., Hu, X., et al. (2025) · Science Advances · doi:10.1126/sciadv.ads2295 · Cited by 47
Engineering Lipid Nanoparticles for mRNA Immunotherapy
Zwolsman, R. C., Darwish, Y. B., Kluza, E., & van der Meel, R. (2025) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.70007 · Cited by 43
Biomimetic liposomes in drug delivery: from design mechanisms to applications
Li, Z., Li, M., & Lu, J. (2025) · Chemical Society Reviews · doi:10.1039/d5cs00440c · Cited by 42
Sophorolipids: Anti-cancer activities and mechanisms
Miceli, R. T., Corr, D. T., Barroso, M., Dogra, N., & Gross, R. A. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116787 · Cited by 41
Spleen-targeted nanosystems for immunomodulation
Wang, F., Lou, J., Gao, X., Zhang, L., Sun, F., Wang, Z., Ji, T., & Qin, Z. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101943 · Cited by 40
RNA-binding proteins in cardiovascular biology and disease: the beat goes on
Völkers, M., Preiß, T., & Hentze, M. W. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00958-z · Cited by 40
Emerging strategies for nanomedicine in autoimmunity
Thatte, A. S., Billingsley, M. M., Weissman, D., Melamed, J. R., & Mitchell, M. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115194 · Cited by 38
Self-citationMacrophage-specific in vivo RNA editing promotes phagocytosis and antitumor immunity in mice
Chen, Y., Chen, X., Zhang, Y., Wang, M., Yang, M., Wang, R. Y., Yan, X., Shao, S., Xin, H., Hu, Q., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adl5800 · Cited by 40
Engineered circular RNA-based DLL3-targeted CAR-T therapy for small cell lung cancer
Cai, J., Liu, Z., Chen, S., Zhang, J., Li, H., Wang, X., Feng, Y., Wang, S., Li, X., Li, Y., et al. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00625-8 · Cited by 41
Chen, Y., Xin, Q., Qiu, J., Zhu, M., Li, Z., Tu, J., Tu, J., & Li, R. (2025) · Experimental Hematology and Oncology · doi:10.1186/s40164-025-00725-5 · Cited by 38
Cardiac fibroblasts in myocardial injury and heart failure
Linthout, S. V., Matz, I., González, A., & Davis, J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf902 · Cited by 47
Magnani, C. F., Myburgh, R., Brunn, S., Chambovey, M., Ponzo, M., Volta, L. G., Manfredi, F., Pellegrino, C. E., Pascolo, S., Miskey, C., et al. (2023) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2023.07.003 · Cited by 38
Bengel, F. M., Diekmann, J., Hess, A., & Jerosch‐Herold, M. (2023) · Journal of Nuclear Medicine · doi:10.2967/jnumed.122.264867 · Cited by 37
The physical landscape of CAR-T synapse
Xiong, Y., Libby, K. A., & Su, X. (2023) · Biophysical Journal · doi:10.1016/j.bpj.2023.09.004 · Cited by 38
Wang, S., Wang, H., Drabek, A. A., Smith, W. S., Liang, F., & Huang, Z. R. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.3c00735 · Cited by 36
Xiao, K., Lai, Y., Yuan, W., Li, S., Liu, X., Xiao, Z., & Xiao, H. (2023) · Interdisciplinary medicine · doi:10.1002/inmd.20230036 · Cited by 41
Kinetics of RNA-LNP delivery and protein expression
Müller, J., Schäffler, N. G., Kellerer, T., Schwake, G., Ligon, T. S., & Rädler, J. O. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114222 · Cited by 36
CAR‐T‐cell products in solid tumors: Progress, challenges, and strategies
Qian, K., Li, G., Zhang, S., Fu, W., Li, T., Zhao, J., Lei, C., Wang, Y., & Hu, S. (2024) · Interdisciplinary medicine · doi:10.1002/inmd.20230047 · Cited by 41
Nanoparticle Targeting Strategies for Lipid and Polymer‐Based Gene Delivery to Immune Cells In Vivo
Jain, M., Yu, X., Schneck, J. P., & Green, J. J. (2024) · Small Science · doi:10.1002/smsc.202400248 · Cited by 41
Koeckerling, D., Reddy, R. K., Barker, J., Eichhorn, C., Divall, P., Howard, J. P., Korell, F., Schmitt, M. W., Dreger, P., Frey, N., et al. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.37222 · Cited by 38
Engineering CAR-T therapies for autoimmune disease and beyond
English, E. P., Swingler, R. N., Patwa, S., Tosun, M., Howard, J. F., Miljković, M. D., & Jewell, C. M. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.ado2084 · Cited by 35
Huston, P. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.904107 · Cited by 42
In vivo gene immunotherapy for cancer
Mai, D. H., June, C. H., & Sheppard, N. C. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo3603 · Cited by 37
Self-citationProgress in nanoparticle-based regulation of immune cells
Fan, Y.-N., Zhao, G., Zhang, Y., Ye, Q., Sun, Y., Shen, S., Liu, Y., Xu, C., & Wang, J. (2023) · Medical Review · doi:10.1515/mr-2022-0047 · Cited by 36
Shen, L., Yang, J., Zuo, C., Xu, J., Ma, L., He, Q., Zhou, X., Ding, X., Wei, L., Jiang, S., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.11.017 · Cited by 34
CAR T-cell therapy in autoimmune diseases: a promising frontier on the horizon
Wu, D., Xu-Monette, Z. Y., Zhou, J., Yang, K., Wang, X., Fan, Y., & Young, K. H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613878 · Cited by 50
Fernández‐Mayola, M., & Thackeray, J. T. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01869-8 · Cited by 34
Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases
Lyu, X., Gupta, L., Tholouli, E., & Chinoy, H. (2023) · Rheumatology · doi:10.1093/rheumatology/kead616 · Cited by 36
Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD
Khalil, B., Linsenmeier, M., Smith, C. L., Shorter, J., & Rossoll, W. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00698-1 · Cited by 36
Myeloid cell-mediated drug delivery: From nanomedicine to cell therapy
Zhang, F., Xu, Z., & Jolly, K. J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114827 · Cited by 35
Current RNA strategies in treating cardiovascular diseases
Chia, S. P. S., Pang, J. K. S., & Soh, B.-S. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.028 · Cited by 34
In vivo manufacture and manipulation of CAR-T cells for better druggability
Hou, R., Zhang, X., Wang, X., Zhao, X., Li, S., Guan, Z., Cao, J., Liu, D., Zheng, J., & Shi, M. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10185-8 · Cited by 32
Lipid-nanoparticle-enabled nucleic acid therapeutics for liver disorders
Arjunan, P., Kathirvelu, D., Mahalingam, G., Goel, A., Zacharaiah, U. G., Srivastava, A., & Marepally, S. K. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.04.015 · Cited by 34
Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases
Baker, D., & June, C. H. (2024) · Cell · doi:10.1016/j.cell.2024.07.056 · Cited by 32
Self-citationChen, Z., Shu, J., Hu, Y., & Mei, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.09.019 · Cited by 33
Advances in cell therapy: progress and challenges in hematological and solid tumors
D'Avanzo, C., Blaeschke, F., Lysandrou, M., Ingelfinger, F., & Zeiser, R. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.10.016 · Cited by 34
Designing next‐generation immune cell therapies with nanomaterials
Chen, K., Wang, W., & Wang, Z. (2025) · BMEMat · doi:10.1002/bmm2.70003 · Cited by 32
Myeloid-Derived Suppressor Cells (MDSCs) in Ovarian Cancer—Looking Back and Forward
Okła, K. (2023) · Cells · doi:10.3390/cells12141912 · Cited by 33
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Kelkar, A. H., Cliff, E. R. S., Jacobson, C. A., Abel, G. A., Dijk, S. W., Krijkamp, E. M., Redd, R., Zurko, J. C., Hamadani, M., Hunink, M. G. M., et al. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2276 · Cited by 31
“Moreover, CAR-T therapies are under investigation for other types of hematologic cancer, solid tumors, and diseases other than cancer (75, 76).”
BackgroundZhang, H., Wang, J., Shen, J., Chen, S., Yuan, H., Zhang, X., Liu, X., Yu, Y., Li, X., Gao, Z., et al. (2024) · iMeta · doi:10.1002/imt2.220 · Cited by 37
CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases
Vuković, J., Abazović, D., Vučetić, D. D., & Medenica, S. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1447147 · Cited by 34
In vivo gene editing of T-cells in lymph nodes for enhanced cancer immunotherapy
Qu, J., Wang, Y., Xiong, C., Wang, M., He, X., Jia, W., Li, C. Y., Zhang, T., Wang, Z., Li, W., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54292-0 · Cited by 34
Tang, C., Zhang, Y., Li, B., Fan, X., Wang, Z., Su, R., Qi, W., & Wang, Y. (2025) · Advanced Materials · doi:10.1002/adma.202415643 · Cited by 35
Developing mRNA Nanomedicines with Advanced Targeting Functions
Wang, J., Cai, L., Li, N., Luo, Z., Ren, H., Zhang, B., & Zhao, Y. (2025) · Nano-Micro Letters · doi:10.1007/s40820-025-01665-9 · Cited by 44
Legumain In Situ Engineering Promotes Efferocytosis of CAR Macrophage to Treat Cardiac Fibrosis
Liu, Z., Chen, C., Zhang, Y., Ji, F., Liu, H., Du, H., Guo, Y., Dong, X., Yang, Z., Han, M., et al. (2025) · Advanced Materials · doi:10.1002/adma.202417831 · Cited by 31
CAR-engineered cell therapies: current understandings and future perspectives
Bayat, M., & Nahand, J. S. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00401-4 · Cited by 37
Ullah, A., Ullah, M., & Lim, S. I. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102396 · Cited by 32
RNA Nanomedicine: Delivery Strategies and Applications
Byun, J., Wu, Y., Park, J.-W., Kim, J. S., Li, Q., Choi, J., Shin, N., Lan, M., Cai, Y., Lee, J., et al. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00860-z · Cited by 33
Modular Bioorthogonal Lipid Nanoparticle Modification Platforms for Cardiac Homing
Cruz‐Samperio, R., Hicks, C. L., Scott, A., Gispert, I., Elani, Y., Richardson, R. J., & Perriman, A. W. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c07811 · Cited by 31
Cardiac fibrogenesis: an immuno-metabolic perspective
Hoque, M. M., Gbadegoye, J. O., Hassan, F. O., Raafat, A., & Lebeche, D. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1336551 · Cited by 33
Targeting Recycling Endosomes to Potentiate mRNA Lipid Nanoparticles
Shin, J., Douglas, C. J., Zhang, S., Seath, C. P., & Bao, H. (2024) · Nano Letters · doi:10.1021/acs.nanolett.3c04415 · Cited by 31
Recent Advancements in mRNA Vaccines: From Target Selection to Delivery Systems
Wu, Z., Sun, W., & Qi, H. (2024) · Vaccines · doi:10.3390/vaccines12080873 · Cited by 34
In vivo CAR cell therapy: from bench to bedside
Jia, X., Chen, Z., Su, L., Ren, A., & Mei, H. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01759-2 · Cited by 35
Single intramuscular injection of self-amplifying RNA of Nppa to treat myocardial infarction
Zhang, K., Tao, H., Zhu, D., Yue, Z., Hu, S., Wu, Y., Yan, N., Hu, Y., Liu, S., Liu, M., et al. (2026) · Science · doi:10.1126/science.adu9394 · Cited by 34
Li, M., Wang, Z., Xie, C., & Xia, X. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.011 · Cited by 38
Activation-inducible CAR expression enables precise control over engineered CAR T cell function
Fräßle, S. P., Tschulik, C., Effenberger, M. J. P., Cletiu, V., Gerget, M., Schober, K., Busch, D. H., Germeroth, L., Stemberger, C., & Poltorak, M. P. (2023) · Communications Biology · doi:10.1038/s42003-023-04978-w · Cited by 31
The Role of the Piezo1 Mechanosensitive Channel in Heart Failure
Yuan, W., Zhang, X., & Fan, X. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45070369 · Cited by 32
Cui, Y., Wang, Y., Wang, S., Du, B., Li, X., & Li, Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12186033 · Cited by 29
Meng, S., Hara, T., Miura, Y., & Ishii, H. (2024) · Cancer Science · doi:10.1111/cas.16285 · Cited by 33
Zhang, L., Lou, W., & Wang, J. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01463-4 · Cited by 35
Impact of Lipid Tail Length on the Organ Selectivity of mRNA-Lipid Nanoparticles
Hashiba, K., Taguchi, M., Sakamoto, S., Otsu, A., Maeda, Y., Suzuki, Y., Ebe, H., Arimichi, O., Harashima, H., & Sato, Y. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c02566 · Cited by 48
Universal CAR cell therapy: Challenges and expanding applications
Wu, Z., Wang, Y., Jin, X. K., & Wang, L. (2024) · Translational Oncology · doi:10.1016/j.tranon.2024.102147 · Cited by 30
Trogocytosis in CAR immune cell therapy: a key mechanism of tumor immune escape
Chen, Y., Xin, Q., Zhu, M., Qiu, J., Qiu, J., Li, R., & Tu, J. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01894-2 · Cited by 34
Linthout, S. V., Stellos, K., Giacca, M., Bertero, E., Cannata, A. N., Carrier, L., García‐Pavía, P., Ghigo, A., González, A., Haugaa, K. H., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3516 · Cited by 33
Loganath, K., Craig, N. J., Barton, A. K., Joshi, S. S., Anagnostopoulos, C., Erba, P. A., Glaudemans, A. W. J. M., Saraste, A., Bucerius, J. A., Lubberink, M., et al. (2024) · Journal of Nuclear Cardiology · doi:10.1016/j.nuclcard.2024.102106 · Cited by 29
Zheng, C., Zhang, L., Sun, Y., Ma, Y., & Zhang, Y. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1564176 · Cited by 37
Lipid nanoparticle screening in nonhuman primates with minimal loss of life
Zenhausern, R., Jang, B., Echeverri, E. S., Gentry, K., Calkins, R., Curran, E. H., Wood, J., Stammen, R. L., Loughrey, D., Chappa, P., et al. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02711-y · Cited by 39
Barriers and solutions for CAR-T therapy in solid tumors
Tu, Z., Chen, Y., Zhang, Z., Meng, W., & Li, L. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00931-7 · Cited by 34
Self-citationSelf-splicing RNA circularization facilitated by intact group I and II introns
Shen, Y. H., Li, B., Dong, L., Tang, W., Ren, J., Chen, F., Zheng, W., Yu, Y. F., Gao, L., & Wei, W. (2025) · Nature Communications · doi:10.1038/s41467-025-62607-y · Cited by 31
Fang, C., Zeng, Z., Ni, B., Wen, X., Fang, Z., Zou, J., & Zhang, G. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1681875 · Cited by 35
Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control
Stock, S., Kluever, A.-K., Fertig, L., Menkhoff, V. D., Subklewe, M., Endres, S., & Kobold, S. (2023) · International Journal of Cancer · doi:10.1002/ijc.34635 · Cited by 32
Vasculature organotropism in drug delivery
Amruta, A., Iannotta, D., Cheetham, S. W., Lammers, T., & Wolfram, J. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.115054 · Cited by 29
Total-Body Positron Emission Tomography
Cherry, S. R., Diekmann, J., & Bengel, F. M. (2023) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2023.06.022 · Cited by 32
Next-generation bNAbs for HIV-1 cure strategies
Schriek, A. I., Aldon, Y., van Gils, M. J., & de Taeye, S. W. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105788 · Cited by 31
Fighting cardiac fibrosis with CAR T cells
Friedman, S. L. (2022) · New England Journal of Medicine · doi:10.1056/nejmcibr2201182 · Cited by 28
Nanomaterials Boost CAR‐T Therapy for Solid Tumors
Long, J., Wang, Y., Jiang, X., Ge, J., Chen, M., Zheng, B., Wang, R., Wang, M., Xu, M., Qi, K., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202304615 · Cited by 34
Reward system activation improves recovery from acute myocardial infarction
Haykin, H., Avishai, E., Krot, M., Ghiringhelli, M., Reshef, M., Abboud, Y., Melamed, S., Merom, S., Boshnak, N., Azulay‐Debby, H., et al. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00491-3 · Cited by 28
Immunomodulatory Therapy for Ischemic Heart Disease
Zhao, X., Williamson, T., Gong, Y., Epstein, J. A., & Fan, Y. (2024) · Circulation · doi:10.1161/circulationaha.124.070368 · Cited by 29
Self-citationIntelligent Design of Lipid Nanoparticles for Enhanced Gene Therapeutics
Yuan, Y., Li, Y., Li, G., Lei, L., Huang, X., Li, M., & Yao, Y. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00925 · Cited by 30
Nanomedicines for cardiovascular diseases: Lessons learned and pathways forward
Mao, Y.-A., Shi, X., Sun, P., Spanos, M., Zhu, L., Chen, H., Wang, X., Su, C., Jin, Y., Wang, X., et al. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123271 · Cited by 29
RETRACTED ARTICLE: Engineered outer membrane vesicles enhance solid tumour CAR-T cell therapy
Li, X., Li, X., Shi, J., Li, Y., Zhang, H., Chen, T., Pang, H., Zhang, S., Luo, S., Liu, F., et al. (2026) · Nature Biomedical Engineering · doi:10.1038/s41551-025-01575-6 · Cited by 31
RetractedRecent progress of gene circuit designs in immune cell therapies
Lee, S., Khalil, A. S., & Wong, W. W. (2022) · Cell Systems · doi:10.1016/j.cels.2022.09.006 · Cited by 29
Immunomodulation of Myocardial Fibrosis
Sikking, M. A., Stroeks, S. L. V. M., Marelli‐Berg, F. M., Heymans, S. R. B., Ludewig, B., & Verdonschot, J. A. J. (2023) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2023.03.015 · Cited by 31
Li, X., Weller, S., Clergeaud, G., & Andresen, T. L. (2024) · Biotechnology Journal · doi:10.1002/biot.202300339 · Cited by 28
Lin, Y.-T., Chen, Y., Luo, Z., & Wu, Y. (2024) · Nanoscale · doi:10.1039/d3nr05768b · Cited by 30
Therapeutic Peptides, Proteins and their Nanostructures for Drug Delivery and Precision Medicine
Kim, H. R., Taslakjian, B., Kim, S., Tirrell, M., & Guler, M. O. (2024) · ChemBioChem · doi:10.1002/cbic.202300831 · Cited by 30
Advances in manufacturing chimeric antigen receptor immune cell therapies
Ramamurthy, A., Tommasi, A. M., & Saha, K. (2024) · Seminars in Immunopathology · doi:10.1007/s00281-024-01019-4 · Cited by 32
Recirculating regulatory T cells mediate thymic regeneration through amphiregulin following damage
Lemarquis, A. L., Kousa, A. I., Argyropoulos, K. V., Jahn, L., Gipson, B., Pierce, J., Serrano-Marin, L., Victor, K., Kanno, Y., Girotra, N. N., et al. (2025) · Immunity · doi:10.1016/j.immuni.2025.01.006 · Cited by 32
Li, G., Ni, C., Wang, J., Zhang, F., Fu, Z., Wang, L., Wang, B., Liu, Y., Zhao, J., Li, M., et al. (2025) · Nature Cardiovascular Research · doi:10.1038/s44161-025-00617-1 · Cited by 34
Harnessing mRNA-lipid nanoparticles as innovative therapies for autoimmune diseases
Razavi, R., Kegel, M., Muscat-Rivera, J., Weissman, D., & Melamed, J. R. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101566 · Cited by 32
Self-citationCellular Senescence, Inflammaging and Cardiovascular Disease
Zanders, L., Arifaj, D., Wagner, J. U. G., & Dimmeler, S. (2026) · Immunological Reviews · doi:10.1111/imr.70084 · Cited by 32
In vivo engineering of CAR-T cells: delivery strategies and clinical translation
Gao, Y., Hu, J., An, N., Wen, X., & Li, C. (2026) · Biomarker Research · doi:10.1186/s40364-026-00899-y · Cited by 29
RNA in Cancer Immunotherapy: Unlocking the Potential of the Immune System
de Mey, W., Esprit, A., Thielemans, K., Breckpot, K., & Franceschini, L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3304 · Cited by 28
Biomaterials for chimeric antigen receptor T cell engineering
Niu, H., Zhao, P., & Sun, W. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2023.04.043 · Cited by 30
Guo, Z., Zeng, C., Shen, Y., Hu, L., Zhang, H., Li, Z., Dong, W. X., Wang, Q., Liu, Q., Wang, Y., et al. (2024) · Nano Letters · doi:10.1021/acs.nanolett.4c01458 · Cited by 28
Yu, X., Wang, J. X., Wang, T., Song, S., Su, H., Huang, H., & Luo, P. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02796-8 · Cited by 27
Chen, H., Hu, K., Tang, Q., Wang, J., Gu, Q., Chen, J., Hu, J., Peng, N., Guo, M., Jiang, Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56703-2 · Cited by 28
Metadata
- Authors
- Rurik, J. G., Tombácz, I., Yadegari, A., Méndez Fernández, P. O., Shewale, S. V., Li, L., Kimura, T., Soliman, O. Y., Papp, T. E., Tam, Y. K., Mui, B. L., Albelda, S. M., Puré, E., June, C. H., Aghajanian, H., Weissman, D., Parhiz, H., & Epstein, J. A.
- Affiliations
- University of Pennsylvania (US)
- Department of Cell and Developmental Biology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Acuitas Therapeutics (Canada) (CA)
- Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
- Corresponding author
- Tombácz, István
- Yadegari, Amir
- Aghajanian, Haig
- Weissman, Drew
- Parhiz, Hamideh
- Epstein, Jonathan A.
- ORCID
- Venue
- Science
- Published
- 2022-01-07
- Volume
- 375
- Issue
- 6576
- Pages
- 91-96
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC9983611
- OpenAlex
- W4206716689
- Cited by
- 1,400
- References
- 36
- Citations by year
- 2026: 375 · 2025: 348 · 2024: 312 · 2023: 215 · 2022: 148
- FWCI
- 106.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL134839, R35HL140018)
- National Institute of Allergy and Infectious Diseases (R01AI124429, U19AI142596, P30AI045008)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Fibrosis and Remodeling
- Keywords
- chimeric antigen receptor T cells, myocardial fibrosis, heart failure, lipid nanoparticles, mRNA delivery, antifibrotic therapy, trogocytosis, cardiac injury
- MeSH terms
- Receptors, Chimeric Antigen, Trogocytosis, Fibroblast Activation Protein Alpha, Animals, Fibroblasts, Fibrosis, Heart Diseases, Heart Failure, Humans, Liposomes, Male, Membrane Proteins, Mice, Inbred C57BL, Myocardium, Endopeptidases, RNA, Messenger, Spleen, T-Lymphocytes, Immunotherapy, Adoptive, CD5 Antigens, Adoptive Transfer, Mice, Nanoparticles, HEK293 Cells, Cell Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.